Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis

Background: Statins have been reported to help prevent the development and the recurrence of deep vein thrombosis (DVT). We conducted a prospective randomized clinical trial to compare the effects of rosuvastatin plus a low-molecular-weight heparin (LMWH), bemiparin, with conventional LMWH therapy in the treatment of DVT. Patients and methods: In total, 234 patients were randomized into two groups, 116 in the LMWH group and 118 in the statin plus LMWH group. All patients underwent lower limb duplex ultrasound and analytic markers at diagnosis and three months of follow-up. The final analysis included 230 patients. Results: No significant differences were observed in D-dimer levels after three months of follow-up between patients treated with LMWH+rosuvastatin compared to the LMWH group (802.51+1062.20 vs. 996.25+1843.37, p = 0.897). The group of patients treated with statins displayed lower levels of CRP (4.17+4.27 vs. 22.39+97.48, p = 0.018) after three months of follow-up. The Villalta scale demonstrated significant differences between groups (3.45+6.03 vs. 7.79+5.58, p = 0.035). There was a significant decrease in PTS incidence (Villalta score > 5) in the rosuvastatin group (38.3% vs. 48.5%, p = 0.019). There were no differences in EuroQol score between groups. Conclusions: Adjuvant rosuvastatin treatment in patients diagnosed of DVT improve CRP levels and diminish PTS incidence.